A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Rosomidnar (Primary)
- Indications Chronic lymphocytic leukaemia; Leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms Brighton
- Sponsors Sierra Oncology
- 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.
- 06 Jun 2016 Status changed from recruiting to suspended, according to a ProNAi Therapeutics media release.
- 06 Jun 2016 According to a ProNAi Therapeutics media release, the company decided to close this study to further enrollment of new subjects based on the interim assessments.